Xencor, Inc Stock Split Ratio
Xencor, Inc (XNCR) reported Stock Split Ratio of 310.00% for the 0-month period ending 2013-11-01, per its 10-Q filed 2014-08-01.
Discontinued › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2016-03-08
- 2013-11-01: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 310.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio 32.20%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 310.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|---|
| 2013-11-01 | 310.00% 10-Q · filed 2014-08-01 | 32.20% 10-K · filed 2016-03-08 | 310.00% 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |